Jul 01,2022

Smart Pen Exposes Missed Basal Insulin Injections and Reveals the Impact on Glycemic Control in Adults With Type 1 Diabetes

Adherence to basal insulin injections and the effects of missed basal insulin injections in adults with type 1 diabetes (T1D) were investigated using data from continuous glucose monitoring (CGM) and smart insulin pen devices in a real-world study.

CLINICAL STUDY

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 01,2022

CeQur is launching a discreet, convenient ‘wearable insulin pen’

CeQur began a pilot commercial launch for the FDA-cleared and CE-marked device in early 2021, which concluded just last month, and now the company is entering the next phase of a limited market release.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 04,2022

Ultrahuman busts out a smart ring to decode metabolic health

The device is designed to work in conjunction with the startup’s existing wearable, a continuous glucose monitor (CGM) sensor-based service it brands ‘Cyborg’, to deepen the quality of insights for users — such as by identifying when a poor glucose response might be linked to a bad night’s sleep, say, or elevated stress levels, rather than putting all the focus on whatever it was the user ate right before their blood sugar spiked.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jul 05,2022

Vida Health’s Virtual Mental Health Program Achieves Meaningful Clinical Outcomes in Reducing Depression and Anxiety

The study, Improvements in Depression Outcomes Following a Digital Cognitive Behavioral Therapy Intervention in a Polychronic Population: Retrospective Study examined the effectiveness of a therapist-supported 12-week, app-based cognitive behavioral therapy (CBT) program in improving symptoms of depression and anxiety in an adult population with a heavy burden of chronic physical disease including obesity and type 2 diabetes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 05,2022

Insights on the Glucose Biosensors Global Market Report to 2027 - Expanding Consumer Expenditures for Point of Care and Home Care Solutions Worldwide Present Opportunities

The Global Glucose Biosensors Market size was estimated at USD 12.98 billion in 2021 and expected to reach USD 14.79 billion in 2022, and is projected to grow at a CAGR 14.20% to reach USD 28.80 billion by 2027.

View Analyst & Ambassador Comments
Go to original news
Jul 06,2022

Indian personalised care platform Zyla Health bags $1M in pre-Series A funding

Zyla Health has recently raised $1 million in a pre-Series A funding round led by venture capital company Seeders. Founded in 2017, Zyla provides personalised care for various health concerns, including heart, kidney, and liver diseases, diabetes, and most recently, COVID-19.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 06,2022

Vida Health Now Offers Musculoskeletal Pain Relief as Part of Its All-in-one Solution

Integrated into Vida’s cardiometabolic-focused, body-and-mind approach to care, Vida’s MSK Pain Relief Program brings a human-led approach combined with a digital therapy exercise program to address the problem of MSK pain.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 06,2022

Global Insulin Pens, Syringes, Pumps And Injectors Market Report 2022: Increase in the Prevalence of Diabetes Globally is Driving Growth

The global insulin pens, syringes, pumps and injectors market is expected to grow from $18.96 billion in 2021 to $20.98 billion in 2022 at a compound annual growth rate (CAGR) of 10.6%. The market is expected to grow to $29.79 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jul 07,2022

Zillion Partners with Dexcom to Integrate Continuous Glucose Monitoring (CGM) Data with its RestoreHealth Program

Zillion announced today its partnership with Dexcom, the leader in real-time continuous glucose monitoring (CGM), to connect Dexcom CGM with Zillion’s platform for use with their RestoreHealth program. This partnership will continue to enhance the RestoreHealth offering to employer and health system patients.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 09,2022

Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring (isCGM) Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9)

Intermittently scanned continuous glucose monitoring (isCGM) is a method to monitor glucose concentrations without using a finger prick. Among persons with type 1 diabetes (T1D), isCGM results in improved glycemic control, less disease burden and improved health-related quality of life (HRQoL). However, it is not clear for which subgroups of patients isCGM is cost-effective. The study aimed to provide a real-world cost-effectiveness perspective.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES